Working… Menu
Trial record 80 of 434 for:    OTITIS

Study of FAECC Scale (Modified FLACC) to Evaluate Ear Pain in Children With Acute Otitis Media

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01588535
Recruitment Status : Completed
First Posted : May 1, 2012
Last Update Posted : May 4, 2015
Information provided by (Responsible Party):
Arbor Pharmaceuticals, Inc.

Brief Summary:
This study is to assess the reliability and validity of the FAECC scale to evaluate pain associated with acute otitis media in children aged 2 months to 5 years.

Condition or disease Intervention/treatment Phase
Pain Otitis Media Drug: benzocaine Drug: placebo Phase 2

Detailed Description:
to assess the reliability and validity of the FAECC pain scale tool in children aged 2 months to 5 years with acute otitis media given AR01 or placebo

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Phase 2, Multicenter, Placebo-controlled, Double-masked, Randomized Study to Demonstrate Reliability and Validity of FAECC Scale (Modified FLACC) to Evaluate Relief of Pain in Subjects With Acute Otitis Media Aged >/=2 Months to <5 Years
Study Start Date : May 2012
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ear Infections

Arm Intervention/treatment
Active Comparator: benzocaine solution
ear drops
Drug: benzocaine
benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
Other Names:
  • Arbor otic
  • AR01

Placebo Comparator: Placebo
ear drops
Drug: placebo
placebo solution, five drops in affected ear canal each hour as needed

Primary Outcome Measures :
  1. Consistency of primary assessor and caregiver FAECC scores using Pearson's correlation coefficient [ Time Frame: up to 120 minutes after first dose and Day 4 ]

Secondary Outcome Measures :
  1. reduction in pain scores from predose to each post-dose time point [ Time Frame: up to 120 minutes after each dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Months to 4 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient has age in the interval 2 months ≤ age < 5.00 years, signs and symptoms of AOM, and moderate to severe pain (current episode ≤ 2 weeks duration). Moderate to severe pain is defined as a score of > or = 4 (on a scale of 0 - 10) for the FAECC scale as assessed by the primary assessor.
  • The patient's parent/guardian must have read and signed the written informed consent prior to study participation.
  • The patient is normally active and otherwise judged to be in good health on the basis of medical history and limited physical examination.

Exclusion Criteria:

  • Patient has perforated tympanic membrane, history of a perforated tympanic membrane in the last 6 months, or if a perforated tympanic membrane could not be ruled out by speculum examination, impedance testing tympanometry, pneumatic otoscopy, or Valsalva maneuver. Patients who are subsequently diagnosed with a perforated membrane during treatment are to be discontinued immediately. Patients with tympanostomy tubes are not allowed.
  • Patient has acute or chronic otitis externa.
  • Patient has chronic otitis media (current episode ≥ 2 weeks).
  • Patient has seborrheic dermatitis involving the affected external ear canal or pinna.
  • Patient has received any otic topical or systemic antibiotic within 14 days prior to study entry (topical or systemic antibiotics for acne will be allowed on a chronic basis for subjects who have been on a stable dose for at least 14 days prior to entry).
  • Patient has received any topical drying agent or over-the-counter therapy for otitis media within 36 hours prior to enrollment.
  • Patient has fever ≤ 102.0 F (oral or equivalent).
  • Patient has known hypersensitivity to the study drug or similar compounds including any of the inactive ingredients.
  • Patient is receiving medication on a chronic basis for pain (including steroidal or non steroidal anti-inflammatory drugs) and has not been on a stable dose for at least 1 month prior to entry into the study.
  • Patient has clinically significant mental illness (to be determined by the Investigator).
  • Patient has been exposed to any investigational agent within 30 days prior to study entry.
  • Patient has been previously enrolled in this study.
  • Patient or caregiver (parent/guardian) has a condition the Investigator believes will interfere with the ability to provide consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk.
  • Patient has a glucose 6-phosphate dehydrogenase deficiency or is taking concomitant medications associated with methemoglobinemia (such as nitrates or nitrites; aniline dyes; or medications, including lidocaine, prilocaine, phenazopyridine hydrochloride [Pyridium], and others).
  • Patient demonstrates clinical signs of anemia. The absolute amount of deoxygenated or abnormal hemoglobin (rather than its percentage) is required for cyanosis to be clinically evident. Patients with moderate-to-severe anemia may not appear cyanotic, even with elevated percentages of deoxygenated or abnormal hemoglobin.
  • Patient has congenital (i.e., hereditary) methemoglobinemia.
  • Patient has a recent history of acute gastroenteritis within 14 days prior to study entry. An association between methemoglobinemia and acute gastroenteritis in infants has been noted in several studies and may be due to acidosis from stool bicarbonate loss impairing the already immature function of the methemoglobin reductase system in these young patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01588535

Layout table for location information
United States, Arkansas
Nda Baptist Clinic
Jonesboro, Arkansas, United States, 72401
United States, Florida
COMMUNITY Medical Research
Miami Beach, Florida, United States, 33141
United States, Iowa
The Iowa Clinic, Pc
West Des Moines, Iowa, United States, 50266
United States, Kentucky
Kentucky Pediatric/Adult Research
Bardstown, Kentucky, United States, 40004
United States, Nebraska
Prairie Fields Family Medicine/Clinical Research Advantage
Fremont, Nebraska, United States, 68025
United States, Nevada
Clinical Research Center
Las Vegas, Nevada, United States, 89104
United States, North Dakota
Odyssey Research
Fargo, North Dakota, United States, 58104
United States, Tennessee
ACCESS CLINICAL TRIALS, Inc. / Centennial Medical Center
Clarksville, Tennessee, United States, 37203
United States, Texas
DiscoveReseach, Inc.
Bryan, Texas, United States, 77082
Research Across America
Carrollton, Texas, United States, 75010
Research Across America
Dallas, Texas, United States, 75234
Dm Clinical Research
Tomball, Texas, United States, 77375
United States, Utah
Foothill Family Clinic
Salt Lake City, Utah, United States, 84109
Salt Lake City, Utah, United States, 84121
Jordon River Family Medicine
South Jordan, Utah, United States, 84095
Sponsors and Collaborators
Arbor Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Laurence Downey, MD Arbor Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Arbor Pharmaceuticals, Inc. Identifier: NCT01588535     History of Changes
Other Study ID Numbers: AR01.004
First Posted: May 1, 2012    Key Record Dates
Last Update Posted: May 4, 2015
Last Verified: March 2015
Keywords provided by Arbor Pharmaceuticals, Inc.:
pain measurement
ear, middle
otitis media
Additional relevant MeSH terms:
Layout table for MeSH terms
Otitis Media
Ear Diseases
Otorhinolaryngologic Diseases
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents